Iron Therapy in Renal Disease: Potential Toxicities

肾脏疾病的铁疗法：潜在毒性

• 批准号: 7426428
• 负责人: Richard A. Zager
• 金额: $ 35.37万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-02 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7426428
• 关键词: Address; Anemia; ApoE knockout mouse; Apolipoprotein E; Atherosclerosis; Biochemical; C-reactive protein; Cholesterol; Cholesterol Homeostasis; Chronic; Data; Development; Dialysis procedure; Disease Progression; Drug Formulations; Drug Kinetics; Elevation; Employee Strikes; End Point; End stage renal failure; Endothelial Cells; Erythrocytes; Erythropoietin; Event; Fibrosis; Goals; Heart; Hepatic; Hepatocyte; Histologic; Hydroxymethylglutaryl-CoA reductase; Immune; In Vitro; Inflammation; Inflammatory; Inflammatory Response; Injury; Iron; Kidney; Kidney Diseases; Kidney Failure; LDL Cholesterol Lipoproteins; Laboratories; Link; Lipid Peroxidation; Lipids; Malignant - descriptor; Mediating; Mediator of activation protein; Mitochondria; Morbidity - disease rate; Mus; Myelogenous; Myeloid Cells; Myocardium; NF-kappa B; Nature; Nephrons; Outcome; Oxidative Stress; Pathway interactions; Patients; Personal Satisfaction; Pharmaceutical Preparations; Physical Dialysis; Plasma; Population; Principal Investigator; Production; Proteins; Proteinuria; Rate; Reactive Oxygen Species; Relative (related person); Renal glomerular disease; Renal tubule structure; Rodent; Serum; Serum Albumin; Testing; Tissues; Toxic effect; Tubulointerstitial Nephritis; Up-Regulation; Work; atherogenesis; cytochrome c; cytotoxicity; ferryl iron; in vivo; mortality; oxidation; oxidized low density lipoprotein; prevent; programs; trend

DESCRIPTION (provided by applicant): Parenteral iron formulations are widely used in patients with end stage renal disease (ESRD) in order to correct, or prevent, iron deficiency, and to enhance red blood cell production in conjunction with exogenous erythropoietin (Epo) therapy. The use of IV iron is likely to expand, given a burgeoning ESRD patient population, and a growing trend towards correcting anemia is pre-ESRD patients. Despite increasing use, little is known about parenteral Fe mediated cytotoxicity, and its potential long-term implications. Indeed, recent data from this laboratory indicate that these compounds exert striking pro-oxidant effects. In vitro and in vivo correlates of this toxicity include the following: i) lipid peroxidation (in plasma, heart, kidney; isolated proximal tubules, myeloid, and endothelial cells); ii) mitochondrial toxicity (ATP depletion; cytochrome c release); iii) anti-proliferation; iv) systemic inflammation (increased ESR; decreased serum albumin); and v) deranged cellular cholesterol homeostasis. The latter culminates in increased endothelial cell, and plasma, cholesterol concentrations, and arises in part from an Fe-induced upregulation of HMG CoA reductase levels and activity. Given these considerations, this application proposes four Specifics Aims: 1) Because 'catalytic' (pro-oxidant) iron is a well recognized mediator of progressive renal injury, and because IV Fe is being administered to pre-ESRD patients, the impact of such therapy on nephron loss in the setting of experimental nephropathy will be addressed. 2) Because atherosclerosis is the leading cause of morbidity and mortality in ESRD patients, and because of iron's potential pro-atherogenic effects, as noted above, the hypothesis that parenteral Fe can accelerate in vivo atherogenesis will be tested. This will be done by administering parenteral irons to pro-atherogenic (ApoE knockout) mice with and without superimposed renal insufficiency. 3) ESRD, and its attendant dialytic therapy, represents a pro-inflammatory state which correlates with poor patient outcomes. Fe can trigger inflammation, in part via the NF Kappa B pathway. Thus, the potential for parenteral Fe to induce, or enhance, systemic inflammatory responses will be sought; and 4) Previous data from this laboratory indicate that substantial differences in toxicity exist amongst currently available parenteral Fe formulations. Potential reasons for these differences will be assessed, with the ultimate goal of defining the safest way of administering parenteral irons to renal disease patients.

描述（由申请人提供）：肠外铁剂制剂广泛用于终末期肾病（ESRD）患者，以纠正或预防铁缺乏，并与外源性促红细胞生成素（Epo）治疗结合增强红细胞生成。鉴于 ESRD 患者群体不断增长，并且 ESRD 前期患者纠正贫血的趋势不断增长，静脉铁剂的使用可能会扩大。尽管使用量不断增加，但人们对肠外铁介导的细胞毒性及其潜在的长期影响知之甚少。事实上，该实验室的最新数据表明这些化合物具有显着的促氧化作用。该毒性的体外和体内相关性包括： i) 脂质过氧化（血浆、心脏、肾脏；分离的近端小管、骨髓和内皮细胞）； ii) 线粒体毒性（ATP 耗尽；细胞色素 c 释放）； iii) 防扩散； iv) 全身炎症（ESR 增加；血清白蛋白减少）； v) 细胞胆固醇稳态紊乱。后者最终导致内皮细胞和血浆胆固醇浓度增加，部分原因是铁诱导的 HMG CoA 还原酶水平和活性上调。鉴于这些考虑，本申请提出了四个具体目标：1) 因为“催化”（促氧化剂）铁是公认的进行性肾损伤的介质，并且因为 IV Fe 正在用于 ESRD 前期患者，所以这种影响将讨论实验性肾病中肾单位损失的治疗。 2) 因为动脉粥样硬化是 ESRD 患者发病和死亡的主要原因，并且由于铁具有潜在的促动脉粥样硬化作用，如上所述，因此将检验肠外铁可以加速体内动脉粥样硬化形成的假设。这将通过给患有或不患有肾功能不全的促动脉粥样硬化（ApoE 敲除）小鼠注射肠外铁剂来完成。 3) ESRD 及其伴随的透析治疗代表一种促炎症状态，与不良的患者预后相关。 Fe 可以部分通过 NF Kappa B 通路引发炎症。因此，我们将寻找肠外铁诱导或增强全身炎症反应的潜力； 4) 该实验室先前的数据表明，目前可用的肠胃外铁制剂之间存在着显着的毒性差异。将评估这些差异的潜在原因，最终目标是确定肾病患者注射铁剂的最安全方法。

项目成果

Uremia impacts renal inflammatory cytokine gene expression in the setting of experimental acute kidney injury.

• DOI: 10.1152/ajprenal.00381.2009
• 发表时间: 2009-08
• 期刊: American journal of physiology. Renal physiology
• 作者: R. Zager;Ali C. M. Johnson;S. Lund